The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
|Videos|August 17, 2021
Dr. Rohit Jain on factors affecting treatment selection in renal cell carcinoma
Author(s)Urology Times staff
Advertisement
Rohit Jain, MD, Moffitt Cancer Center, discusses risk status and other factors he considers in treatment selection for patients with advanced renal cell carcinoma (RCC).
Note: this interview was filmed before the
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Urology Times
1
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
2
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC
3
How PSMA-PET shapes staging and recurrence workup in prostate cancer
4
Michael Cookson, MD, reacts to Anktiva’s expanded approval in NMIBC
5